GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and ...

A new biostatistical modeling approach has the potential to support health decisions by pinpointing where HIV is concentrated ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to case presentations ...

For adults with virologically suppressed HIV-1, once-weekly oral islatravir-lenacapavir (ISL/LEN) is noninferior to ...

CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to prevent viral rebound after ART stopped.

Advanced Practice Registered Nurse Rashan Jones is the second person charged over HIV outreach work involving First Coast ...

Researchers at the UC Davis School of Medicine have identified a naturally occurring metabolite that repairs gut damage ...

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer ...

HSA, from Lactiplantibacillus plantarum, repaired HIV-related gut damage and improved ART effectiveness in monkeys.

Immune-based strategies to achieve HIV remission are increasingly focusing on ways to boost the body’s ability to control ...

Q2 2026 earnings call recap: raised HIV/PrEP outlook, Yeztugo momentum, Veklury reset, and deal-driven EPS hit.

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.